Abstract
Hypercalcemia occurring in patients with advanced breast cancer (BC) is generally due to osteolytic metastases or to the activity of circulating tumor-derived products. In these conditions, the production of endogenous PTH is reduced. The frequency of hypercalcemia due to primary hyperparathyroidism in breast cancer is unknown. We examined the occurrence of primary hyperparathyroidism in a large group of women with treated BC. A total of 100 consecutive women aged 28–80 years with treated breast cancer were enrolled. One hundred and two healthy age-matched women and 60 age-matched female patients with differentiated thyroid carcinoma examined before thyroidectomy were used as controls. Intact serum PTH and serum calcium were measured in all patients and controls. Hypercalcemia associated with elevated serum PTH concentration indicating primary hyperparathyroidism was found in 7 BC patients (7%) and in none of healthy women or patients with thyroid cancer. The pre-operative staging of BC patients with primary hyperparathyroidism was I in six and II in one of them, and no patient had evidence of distant metastases. A parathyroid adenoma was found in all 6 BC patients submitted to neck exploration, one patient refused surgery. Serum calcium and PTH concentrations returned to normal levels after surgery. Two BC patients had increased serum PTH and normal calcium concentrations. One of them had low serum 25-hydroxyvitamin D [25(OH)D]. One patient with spread bone metastases had neoplastic hypercalcemia with undetectable serum PTH concentration. All remaining 90 BC patients had serum calcium and PTH concentrations within normal limits, but their mean (±SD) values (9.6±0.5 mg/dl for serum calcium, 38.0±16.4 mg/dl for serum PTH ) were slightly but significantly greater than in normal controls (9.3±0.5 mg/dl, p=0.003 and 27.9±10.6 pg/ml, p=0.0001, respectively) and in patients with thyroid cancer (9.2±0.6 mg/dl, p=0.001 and 26.2±11.0 pg/ml, p=0.001), with no relationship with clinical staging or anti-tumor therapy. In conclusion: 1) an increased frequency of parathyroid adenoma was found in BC patients with mildly aggressive neoplastic disease; 2) in BC patients with no evidence of primary hyperparathyroidism mean serum PTH and calcium concentrations were significantly greater than in healthy controls and in patients with thyroid carcinoma; and 3) this finding was unrelated to clinical staging or anti-tumor therapy. Thus, primary hyperparathyroidism should be considered as a possible cause of hypercalcemia in patients with non-aggressive breast cancer. We suggest that serum PTH should be determined in all BC patients with increased serum calcium concentration, especially in those with no evidence of metastatic disease.
Similar content being viewed by others
References
Mundy G.R. Hypercalcemia of malignancy revisited. J. Clin. Invest. 1998, 82: 1–6.
Mundy G.R., Ibbotson K.J., D’Souza S.M., Simpson E.L., Jacobs J.W., Martin T.J. The hypercalcemia of cancer: clinical implication and pathogenic mechanisms. N. Engl. J. Med. 1984, 28: 1718–1727.
Isales C., Stewart A.F. Hypercalcemia in breast cancer. Am. J. Med. 1987, 82: 1143–1147.
Francini G., Petrioli R., Maioli E. Hypercalcemia in breast cancer. Clin. Exp. Metastasis 1993, 11: 359–367.
Broadus A.E., Mangin M., Ikeda K., Insogna K.L., Weir E.C., Burtis W., Stewart A.F. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N. Engl. J. Med. 1988, 319: 556–600.
Ralston S.H. The pathogenesis of humoral hypercalcemia of malignancy. Lancet 1987, 19: 1443–1445.
Strewler G.J. The physiology of parathyroid hormone-related protein. N. Engl. J. Med. 2000, 342: 177–185.
Grill V., Ho P., Body J.J., Johanson N., Lee S.C., Kukreja S.C. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J. Clin. Endocrinol. Metab. 1991, 73: 1309–1315.
Lee J.K., Ghuang M.J., Lu C.C., Hao L.J., Yang C.Y., Han T.M., Lam H.C. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population. J. Endocrinol. Invest. 1997, 20: 404–409.
Ratcliffe W.A., Hutchesson A.C., Bundred N.J., Ratcliffe J.G. Role of assays for parathyroid-hormone-related-protein in investigation of hypercalcemia. Lancet 1992, 339: 164–167.
Cryer P.E., Hill J.H. Pancreatic islet cell carcinoma with hypercalcemia and hypergastrinemia. Cancer 1976, 3876: 2217–2221.
Besler L., Boissel P., Conroy T., Grosdidier J. Pancreatic islet cell carcinoma with hypercalcemia: complete remission after 5 years of hypercalcemia and chemotherapy. Am. J. Gastroenterol. 1991, 86: 635–638.
Axelrod D.M., Bockman R.S., Wong G.Y., Osborne M.P., Kinne D.W., Brennan M.F. Distinguishing features of primary hyperparathyroidism in patients with breast cancer. Cancer 1987, 60: 1624–1630.
NIH Consensus Development Conference Statement on Primary Hyperparathyroidism. J. Bone Miner. Res. 1991, 6: s9–s13.
World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series No 843, WHO, Geneva, 1994.
Boonstra C.E., Jackson C.E. Serum calcium survey for hyperparathyroidism: results in 50,000 clinic patients. Am. J. Clin. Pathol. 1990, 55: 523–526.
Vichayanrat A., Avramides A., Gardner B., Carter A.C. Primary hyperparathyroidism and breast cancer. Am. J. Med. 1976, 61: 136–139.
Rao S.D., Frame B., Miller M.J., Kleerekopern M., Block M.A., Parfitt A.M. Hyperparathyroidism following head and neck irradiation. Arch. Intern. Med. 1980, 140: 205–207.
Mary Beard C., Hunter H. III, Michael F.W., Andersonn J.A., Earle J.D, Melton III L.J. Therapeutic radiation and hyperparathyroidism. A case control study in Rochester. Minn. Arch. Internal Med. 1989, 149: 1887–1890.
Hedman I., Tisell L.E. Associated hyperparathyroidism and non medullary thyroid carcinoma: the etiologic role of radiation. Surgery 1983, 95: 392–397.
Author information
Authors and Affiliations
Additional information
This work was supported by grants from Consiglio Nazionale delle Ricerche (CNR, Rome, Italy) (grant no. 95.0101 P.F. 40) and from Ministero della Università e della Ricerca Scientifica e Tecnologica (40%, Rome, Italy). Target Project: “Biologia e Patologia delle Interazioni Cellula-Matrice”. Dub Project “Osteoporosi e Osteopatie Metaboliche“.
Rights and permissions
About this article
Cite this article
Fierabracci, P., Pinchera, A., Miccoli, P. et al. Increased prevalence of primary hyperparathyroidism in treated breast cancer. J Endocrinol Invest 24, 315–320 (2001). https://doi.org/10.1007/BF03343867
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343867